The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference. Symptoms following discontinuation were assessed through the Discontinuation-Emergent Signs and Symptoms checklist in three studies. Long-term (⩽52 weeks) tolerability was evaluated in five open-label extension studies. Patients ( n =5701) were acutely treated with either placebo ( n=1817), vortioxetine (5–20mg/day; n=3018), venlafaxine XR (225mg/day; n=113) or duloxetine (60mg/day; n=753). The withdrawal rate due to TEAEs during treatment with vortioxetine (5–20mg/day) was 4.5–7.8%, compared with placebo (3.6%), venlafaxine XR (14.2%) or duloxetine (8.8%). Common TEAEs (incidence ⩾5% and >2 × placebo) with vortioxetine (5–20mg/day) were nausea (20.9–31.2%) and vomiting (2.9–6.5%). For vortioxetine (5–20mg/day), the incidence of TEAEs associated with insomnia was 2.0–5.1% versus 4.0% for placebo, and with sexual dysfunction 1.6–1.8% versus 1.0% for placebo. Discontinuation symptoms as assessed by the mean Discontinuation-Emergent Signs and Symptoms total score after abrupt discontinuation were comparable to placebo in the first and second week. Vortioxetine had no effect relative to placebo on clinical laboratory parameters, body weight, heart rate or blood pressure. Vortioxetine showed no clinically relevant effect on ECG parameters, including the QTcF interval. In long-term treatment, no new types of TEAEs were seen; the mean weight gain was 0.7–0.8kg. Thus, vortioxetine (5–20mg/day) appears safe and generally well tolerated in the treatment of major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · cited 2×
“The tolerability of antidepressant treatment affects quality of life and adherence with medication (Cleare et al., 2015).”
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · cited 1×
“Vortioxetine is a novel antidepressant with multimodal activity: it is a 5HT3, 5HT7 and 5HT1D receptor antagonist, a 5HT1B partial agonist, a 5HT1A agonist and an inhibitor of the serotonin (5-HT) transporter (Bang-Andersen et al., 2011).”
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · cited 3×
“There is evidence that antidepressants that are also 5-HT1A receptor agonists (e.g. vortioxetine and vilazodone) may facilitate sexual performance in male rats in the presence of high levels of serotonin that usually inhibit sexual function (Sanchez et al., 2015).”
InfluentialKatona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 3×
“In a randomized placebo-controlled study in elderly patients with MDD treated with vortioxetine 5 mg (Katona et al., 2012) nausea was the only TEAE reported with an incidence ⩾5% that occurred > 2 x more frequently in the vortioxetine group than in the placebo group (21.8% vs. 8.3%).”
InfluentialMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · cited 1×
“For patients with major depressive disorder (MDD) long-term treatment (at least 6–12 months) is recommended for patients who have responded to acute treatment to prevent relapse and recurrence (Cleare et al., 2015; Lam et al., 2009).”
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P., Chen, Y., & Thase, M. E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07470 · Cited by 150
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
Research works printed but not linked: 26
- 10.1097/YIC.0000000000000010 · DOI · Paper page
- 10.1111/bcpt.12256 · DOI
- 10.1185/03007995.2012.725035 · DOI · Paper page
- 10.1016/j.euroneuro.2011.11.008 · DOI
- 10.1016/j.euroneuro.2012.07.012 · DOI
- 10.1007/s40261-013-0117-6 · DOI · Paper page
- Chen G, 2012, Clin Pharm Ther, 91, S39, 10.1038/clpt.2012.27 · DOI
- Chen G, 2011, J Clin Pharmacol, 51, 1350, 10.1177/0091270010368411 · doi:10.1177/0091270010368411
- 10.1002/jcph.456 · DOI
- 10.1111/ijcp.12350 · DOI · Paper page
- 10.1016/S0924-977X(13)70510-8 · doi:10.1016/s0924-977x(13)70510-8
- 10.1016/S0924-977X(12)70383-8 · DOI
- 10.1124/dmd.112.044610 · DOI
- 10.1097/YIC.0000000000000081 · DOI · Paper page
- 10.1111/jsm.12980 · DOI · Paper page
- 10.4088/JCP.14m09335 · DOI · Paper page
- 10.1185/03007995.2012.761600 · DOI · Paper page
- 10.1111/ijcp.12328 · DOI · Paper page
- 10.1002/hup.2371 · DOI · Paper page
- Mayer M, 2012, Clin Pharmacol Drug Dev, 1, 188
- 10.1016/S0006-3223(98)00126-7 · DOI · Paper page
- 10.1016/j.euroneuro.2012.07.011 · DOI
- 10.1038/clpt.2013.39 · DOI · Paper page
- Wang Y, 2011, Clin Pharm Ther, 89, S71
- 10.1002/cpdd.51 · DOI
- 10.1177/0269881115599387 · DOI · Paper page
Cited by
Cognitive impairment in depression: recent advances and novel treatments
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384
Antidepressant‐induced sexual dysfunction
Rothmore, J. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50522 · Cited by 229
Fagiolini, A., Florea, I., Loft, H., & Christensen, M. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.106 · Cited by 127
Self-citationVortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Vortioxetine: A Review in Cognitive Dysfunction in Depression
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0655-3 · Cited by 90
Metadata
- Authors
- Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-02-09
- Volume
- 30
- Issue
- 3
- Pages
- 242-252
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2270496518
- Cited by
- 187
- References
- 12
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. https://app.cochat.ai/papers/10.1177/0269881116628440
- The paper
- Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016). The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116628440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.